Related Experiment Video
Updated: Nov 15, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Prognostic Value of MicroRNA-20b in Acute Myeloid Leukemia
Zhiheng Cheng1,2,3, Yifeng Dai2, Wenhui Huang1,3
1Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Abstract:
Acute myeloid leukemia (AML) is a highly heterogeneous disease that requires fine-grained risk stratification for the best prognosis of patients. As a class of small non-coding RNAs with important biological functions, microRNAs play a crucial role in the pathogenesis of AML. To assess the prognostic impact of miR-20b on AML in the presence of other clinical and molecular factors, we screened 90 AML patients receiving chemotherapy only and 74 also undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) from the Cancer Genome Atlas (TCGA) database. In the chemotherapy-only group, high miR-20b expression subgroup had shorter event-free survival (EFS) and overall survival (OS, both P < 0.001); whereas, there were no significant differences in EFS and OS between high and low expression subgroups in the allo-HSCT group. Then we divided all patients into high and low expression groups based on median miR-20b expression level. In the high expression group, patients treated with allo-HSCT had longer EFS and OS than those with chemotherapy alone (both P < 0.01); however, there were no significant differences in EFS and OS between different treatment subgroups in the low expression group. Further analysis showed that miR-20b was negatively correlated with genes in "ribosome," "myeloid leukocyte mediated immunity," and "DNA replication" signaling pathways. ORAI2, the gene with the strongest correlation with miR-20b, also had significant prognostic value in patients undergoing chemotherapy but not in the allo-HSCT group. In conclusion, our findings suggest that high miR-20b expression is a poor prognostic indicator for AML, but allo-HSCT may override its prognostic impact.
Insights
High microRNA-20b (miR-20b) expression indicates a poor prognosis for acute myeloid leukemia (AML) patients treated with chemotherapy alone. However, allogeneic hematopoietic stem cell transplantation (allo-HSCT) may overcome this negative impact.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Acute myeloid leukemia (AML) is a complex cancer requiring precise risk stratification for effective patient management.
- MicroRNAs (miRNAs) are small non-coding RNAs involved in crucial biological processes and are implicated in AML development.
Purpose of the Study:
- To investigate the prognostic significance of miR-20b in AML patients.
- To determine if miR-20b expression levels influence treatment outcomes based on chemotherapy versus allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Main Methods:
- Retrospective analysis of 90 AML patients receiving chemotherapy and 74 undergoing allo-HSCT from The Cancer Genome Atlas (TCGA) database.
- Correlation analysis between miR-20b expression and clinical outcomes (event-free survival and overall survival).
- Investigated correlations between miR-20b and specific signaling pathways and genes, including ORAI2.
Main Results:
- In the chemotherapy-only group, high miR-20b expression correlated with significantly shorter event-free survival (EFS) and overall survival (OS).
- No significant difference in EFS or OS was observed between high and low miR-20b expression groups in the allo-HSCT cohort.
- Patients with high miR-20b expression showed improved EFS and OS with allo-HSCT compared to chemotherapy alone; this difference was not significant in the low miR-20b expression group.
- miR-20b negatively correlated with genes in "ribosome," "myeloid leukocyte mediated immunity," and "DNA replication" pathways. ORAI2 showed significant prognostic value in chemotherapy patients but not in the allo-HSCT group.
Conclusions:
- High miR-20b expression serves as a poor prognostic biomarker in AML, particularly for patients treated with chemotherapy.
- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to mitigate the adverse prognostic impact of high miR-20b expression in AML.
- miR-20b's influence on AML prognosis is context-dependent, varying with treatment modality.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs